<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495716</url>
  </required_header>
  <id_info>
    <org_study_id>32545</org_study_id>
    <secondary_id>K23AI071257-01A1</secondary_id>
    <nct_id>NCT00495716</nct_id>
  </id_info>
  <brief_title>Effect of HSV-2 Suppressive Therapy on Sexual Behavior</brief_title>
  <official_title>Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine what effect suppressive therapy has on sexual
      behavior and quality of life among persons with genital herpes (HSV) who have multiple sex
      partners.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to conduct a randomized controlled trial of chronic suppressive acyclovir, 400 mg
      orally twice daily (standard dose) versus episodic acyclovir for treatment of genital herpes
      recurrences. We will enroll 500 HSV-2 seropositive single persons (250 per arm), stratified
      by gender and history of symptomatic genital herpes, and prospectively follow them for 1 year
      to assess sexual behavior, adherence to therapy, and herpes-related quality of life. These
      outcomes will be measured by self-report in a confidential, computer-based assessment. We
      plan to use data from this trial to model the effect that increasing the proportion of
      sexually-active HSV-2 infected persons taking suppressive therapy will have on
      population-level incidence and prevalence of HSV-2.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigator relocated and study funding ended.
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effect of Suppressive Antiviral Therapy on Sexual Behavior Among HSV-2 Seropositive Persons With Multiple Sexual Partners.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Acceptability and Adherence to Suppressive Antiviral Therapy for HSV-2 Prevention Among Single, Sexually Active Men and Women.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Genital Herpes</condition>
  <arm_group>
    <arm_group_label>Episodic Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suppressive Therapy Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg acyclovir orally twice daily for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyclovir</intervention_name>
    <description>800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence</description>
    <arm_group_label>Episodic Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acyclovir</intervention_name>
    <description>400 mg acyclovir orally twice daily for 1 year</description>
    <arm_group_label>Suppressive Therapy Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  HSV-2 seropositive by Western blot OR documented culture positive for HSV-2 from
             anogenital site

          -  2 or more vaginal or anal sex partners in the past 12 months

          -  Not currently in a monogamous sexual relationship of &gt;= 6 months duration

          -  Willing and able to be randomized and comply with the study protocol

        Exclusion Criteria:

          -  Pregnancy or intention to become pregnant within the next year

          -  Suppressive therapy with acyclovir, valacyclovir, or famciclovir within 2 weeks of
             enrollment/randomization

          -  6 or more symptomatic herpes recurrences in the prior 12 months or in the 12 months
             prior to starting suppressive therapy if on suppressive therapy during the prior 12
             months

          -  HIV seropositive or known immunocompromising medical condition. HIV negative test must
             be performed within 60 days of Visit 1 (enrollment/randomization). For current or
             former participants in HIV vaccine clinical trials for whom HIV vaccine-induced
             seropositivity potentially leading to vaccine study unblinding may be a concern, a
             report from the Seattle HVTU documenting that the participant is HIV uninfected based
             on HIV testing done within 60 days of Visit 1 will be accepted in lieu of HIV testing
             done at our clinic.

          -  Intention to move from the Seattle area within the next year

          -  Known allergy, intolerance, or medical contraindication to acyclovir

          -  Inability to understand, speak, and read English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Wald, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>July 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <results_first_submitted>March 15, 2018</results_first_submitted>
  <results_first_submitted_qc>January 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2020</results_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Anna Wald</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Episodic Treatment Arm</title>
          <description>800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
acyclovir: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence</description>
        </group>
        <group group_id="P2">
          <title>Suppressive Therapy Arm</title>
          <description>400 mg acyclovir orally twice daily for 1 year
acyclovir: 400 mg acyclovir orally twice daily for 1 year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Episodic Treatment Arm</title>
          <description>800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
acyclovir: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence</description>
        </group>
        <group group_id="B2">
          <title>Suppressive Therapy Arm</title>
          <description>400 mg acyclovir orally twice daily for 1 year
acyclovir: 400 mg acyclovir orally twice daily for 1 year</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="18" upper_limit="79"/>
                    <measurement group_id="B2" value="39" lower_limit="22" upper_limit="63"/>
                    <measurement group_id="B3" value="39" lower_limit="18" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Suppressive Antiviral Therapy on Sexual Behavior Among HSV-2 Seropositive Persons With Multiple Sexual Partners.</title>
        <time_frame>1 year</time_frame>
        <population>Study terminated; investigator relocated and study funding ended. Results cannot be analyzed because data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Episodic Treatment Arm</title>
            <description>800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
acyclovir: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence</description>
          </group>
          <group group_id="O2">
            <title>Suppressive Therapy Arm</title>
            <description>400 mg acyclovir orally twice daily for 1 year
acyclovir: 400 mg acyclovir orally twice daily for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Suppressive Antiviral Therapy on Sexual Behavior Among HSV-2 Seropositive Persons With Multiple Sexual Partners.</title>
          <population>Study terminated; investigator relocated and study funding ended. Results cannot be analyzed because data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Acceptability and Adherence to Suppressive Antiviral Therapy for HSV-2 Prevention Among Single, Sexually Active Men and Women.</title>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Episodic Treatment Arm</title>
          <description>800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
acyclovir: 800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence</description>
        </group>
        <group group_id="E2">
          <title>Suppressive Therapy Arm</title>
          <description>400 mg acyclovir orally twice daily for 1 year
acyclovir: 400 mg acyclovir orally twice daily for 1 year</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study terminated; investigator relocated and study funding ended. Results cannot be analyzed because data were not collected.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinic Director</name_or_title>
      <organization>University of Washington Virology Research Clinic</organization>
      <phone>206-520-4340</phone>
      <email>vrc@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

